Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Adaptimmune Therapeutics Ownership Summary


Adaptimmune Therapeutics is owned by 0.32% institutional investors, 0.63% insiders, and 99.05% retail investors. Long focus capital management is the largest institutional shareholder, holding 7.03% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.00% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAdaptimmune Therapeutics0.32%0.63%99.05%
SectorHealthcare Stocks 232.51%10.72%-143.22%
IndustryBiotech Stocks 384.55%10.58%-295.13%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Long focus capital management18.58M7.03%$2.42M
Bank of america corp /de/4.65M1.92%$4.53M
Empirical finance800.00K0.30%$104.00K
B. riley wealth advisors500.00K0.19%$65.00K
Rathbones group432.82K0.16%$56.27M
Fmr340.41K0.13%$44.25K
Blackrock193.76K0.08%$188.89K
Xtx topco102.50K0.04%$13.32K
State of tennessee, treasury department73.38K0.03%$9.54K
Northern trust48.58K0.02%$6.32K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Long focus capital management18.58M0.08%$2.42M
Empirical finance800.00K0.01%$104.00K
B. riley wealth advisors500.00K0.00%$65.00K
Prosperity wealth management19.23K0.00%$2.50K
Xtx topco102.50K0.00%$13.32K
Bank of america corp /de/4.65M0.00%$4.53M
Carmichael hill & associates525.000.00%$512.00
Lindbrook capital4.61K0.00%$2.48K
Rathbones group432.82K0.00%$56.27M
Global retirement partners6.00K0.00%$3.23K

Top Buyers

HolderShares% AssetsChange
B. riley wealth advisors500.00K0.00%500.00K
Millennium management94.28K-64.72K
Xtx topco102.50K0.00%22.48K
Simplex trading12.42K-12.42K
Rockefeller capital management12.17K-12.17K

Top Sellers

HolderShares% AssetsChange
Matrix capital management company, lp---37.68M
Ecor1 capital---27.40M
Two seas capital lp---22.58M
Nea management company---17.08M
Baillie gifford---11.82M

New Positions

HolderShares% AssetsChangeValue
B. riley wealth advisors500.00K0.00%500.00K$65.00K
Simplex trading12.42K-12.42K$1.00K
Rockefeller capital management12.17K-12.17K$1.58K
Garde capital750.00-750.00$180.00

Sold Out

HolderChange
National bank of canada /fi/-10.00
Sbi securities-10.00
Td waterhouse canada-14.00
Farther finance advisors-20.00
Koesten, hirschmann & crabtree-47.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202520-69.23%846,318-99.27%-0.57%8-60.00%1-94.74%
Jun 30, 202564-8.57%115,507,217-0.49%713.22%18-30.77%2017.65%
Mar 31, 20255-93.83%42,678,699-65.69%24.21%2-93.55%2-90.48%
Dec 31, 202479-2.47%124,313,247-18.02%88.30%30-18.92%2140.00%
Sep 30, 202479-1.25%151,643,820-1.46%591.46%3656.52%15-31.82%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Edinburgh Worldwide Ord5.28M2.00%-
Baillie Gifford Global Discovery A Acc3.29M1.28%-20.71K
Baillie Gifford WW Discovery B USD Acc1.59M0.62%-6.22K
JPM Thematics Genetic Thrps C2 Acc USD913.17K0.36%-26.08K
JPM Thematics Genetic Thrps C2 dist USD881.69K0.34%-
Galileo - Biotech Innovation Fund S USD752.46K0.28%-
Mercer Global Small Cap Equity M-5£635.81K0.25%-
Mercer Global Small Cap Equity M-3£484.78K0.19%84.40K
SPDR® Portfolio Developed Wld ex-US ETF296.36K0.11%-
A4Investments SICAV SIF ACCI IlanaA2EURH221.29K0.09%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 02, 2025Wood Gavin Chief Financial OfficerSell$950.40
Aug 28, 2025Bertrand William C JR Chief Operating OfficerSell$2.09K
Aug 15, 2025Behbahani Ali-Sell$53.11K
Aug 18, 2025Behbahani Ali-Sell$176.06K
Jul 30, 2025EcoR1 Capital, LLC-Sell$2.80M

Insider Transactions Trends


DateBuySell
2025 Q3-7
2025 Q1-17
2024 Q3--
2024 Q2-1
2024 Q1-19

ADAP Ownership FAQ


Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 0.32%, followed by 0.63% insiders and 99.05% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 384.55%, which Adaptimmune Therapeutics falls below.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Long focus capital management (18.58M shares, 7.03%), Bank of america corp /de/ (4.65M shares, 1.92%), and Empirical finance (800K shares, 0.30%). Together, they hold 9.26% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

Yes, BlackRock owns 0.08% of Adaptimmune Therapeutics, totaling 193.76K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 188.89K$. In the last quarter, BlackRock decreased its holdings by -95.931K shares, a -33.12% change.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Long focus capital management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.08% of its assets in 18.58M Adaptimmune Therapeutics shares, valued at 2.42M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.00% of its total shares outstanding invested in 5.28M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools